[{"id":"44c07294-8489-4b3a-b2ed-b2c7e11ad982","acronym":"NCI#10057","url":"https://clinicaltrials.gov/study/NCT02978625","created_at":"2021-01-18T14:39:10.615Z","updated_at":"2025-02-25T13:48:20.165Z","phase":"Phase 2","brief_title":"Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers","source_id_and_acronym":"NCT02978625 - NCI#10057","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • ALK • NECTIN1","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["PD-L1 • ALK • NECTIN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Imlygic (talimogene laherparepvec) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 09/27/2017","start_date":" 09/27/2017","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-21"},{"id":"6a48c7f0-faef-41c8-a9fa-31b1481860b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02779855","created_at":"2021-01-18T13:37:46.654Z","updated_at":"2025-02-25T15:25:27.556Z","phase":"Phase 1/2","brief_title":"Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer","source_id_and_acronym":"NCT02779855","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 amplification","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Imlygic (talimogene laherparepvec)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/02/2017","start_date":" 05/02/2017","primary_txt":" Primary completion: 09/20/2020","primary_completion_date":" 09/20/2020","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2025-02-10"},{"id":"4b76673c-cd8f-4b3e-aab1-a119e574fcaa","acronym":"MASTERKEY318","url":"https://clinicaltrials.gov/study/NCT02509507","created_at":"2021-01-18T12:07:01.792Z","updated_at":"2025-02-25T16:14:58.621Z","phase":"Phase 1/2","brief_title":"Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611","source_id_and_acronym":"NCT02509507 - MASTERKEY318","lead_sponsor":"Amgen","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • ER negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Imlygic (talimogene laherparepvec)"],"overall_status":"Completed","enrollment":" Enrollment 127","initiation":"Initiation: 02/05/2016","start_date":" 02/05/2016","primary_txt":" Primary completion: 02/14/2022","primary_completion_date":" 02/14/2022","study_txt":" Completion: 07/11/2023","study_completion_date":" 07/11/2023","last_update_posted":"2024-08-06"},{"id":"6c2e39ce-123b-43b3-a0b9-013302070a36","acronym":"","url":"https://clinicaltrials.gov/study/NCT01740297","created_at":"2021-01-17T17:36:18.459Z","updated_at":"2024-07-02T16:35:03.840Z","phase":"Phase 1/2","brief_title":"Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma","source_id_and_acronym":"NCT01740297","lead_sponsor":"Amgen","biomarkers":" BRAF • PD-1 • CTLA4","pipe":" | ","alterations":" BRAF mutation • BRAF wild-type","tags":["BRAF • PD-1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • Imlygic (talimogene laherparepvec)"],"overall_status":"Completed","enrollment":" Enrollment 217","initiation":"Initiation: 02/07/2013","start_date":" 02/07/2013","primary_txt":" Primary completion: 08/23/2016","primary_completion_date":" 08/23/2016","study_txt":" Completion: 03/09/2021","study_completion_date":" 03/09/2021","last_update_posted":"2024-05-14"},{"id":"2283fe0f-f8ab-4a43-8da4-f3e6948ef310","acronym":"","url":"https://clinicaltrials.gov/study/NCT03842943","created_at":"2021-01-18T18:58:12.448Z","updated_at":"2024-07-02T16:35:06.412Z","phase":"Phase 2","brief_title":"Neoadjuvant Combination Immunotherapy for Stage III Melanoma","source_id_and_acronym":"NCT03842943","lead_sponsor":"University of Louisville","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Imlygic (talimogene laherparepvec)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 07/03/2019","start_date":" 07/03/2019","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-05-02"},{"id":"cb96adf5-8ef2-4aba-9494-0926838dbfe1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02923778","created_at":"2023-12-07T00:15:50.855Z","updated_at":"2024-07-02T16:35:16.265Z","phase":"Phase 2","brief_title":"Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery","source_id_and_acronym":"NCT02923778","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imlygic (talimogene laherparepvec)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/31/2019","start_date":" 12/31/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-06"},{"id":"3e645071-4216-4aec-a0bd-0e6e40f1d02a","acronym":"S1607","url":"https://clinicaltrials.gov/study/NCT02965716","created_at":"2021-01-18T14:34:36.597Z","updated_at":"2024-07-02T16:35:26.748Z","phase":"Phase 2","brief_title":"Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma","source_id_and_acronym":"NCT02965716 - S1607","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • CD8 • PD-1 • CD14 • FOXP3 • CD80 • CD86","pipe":" | ","alterations":" CD8 expression","tags":["TMB • CD8 • PD-1 • CD14 • FOXP3 • CD80 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Imlygic (talimogene laherparepvec)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 06/05/2018","start_date":" 06/05/2018","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 11/05/2024","study_completion_date":" 11/05/2024","last_update_posted":"2023-12-08"},{"id":"e46679fd-4818-4ca0-bb8c-b7e825fdcfd9","acronym":"NIVEC","url":"https://clinicaltrials.gov/study/NCT04330430","created_at":"2021-01-18T20:58:18.317Z","updated_at":"2024-07-02T16:35:34.731Z","phase":"Phase 2","brief_title":"Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (Stage IIIB/C/D-IV M1a) Melanoma With Injectable Disease","source_id_and_acronym":"NCT04330430 - NIVEC","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Imlygic (talimogene laherparepvec)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 09/08/2020","start_date":" 09/08/2020","primary_txt":" Primary completion: 04/09/2023","primary_completion_date":" 04/09/2023","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-10-04"},{"id":"59a6a112-d198-4a26-abd5-aa150b6e5ffb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03064763","created_at":"2021-01-18T15:05:45.259Z","updated_at":"2024-07-02T16:35:40.563Z","phase":"Phase 1","brief_title":"Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma","source_id_and_acronym":"NCT03064763","lead_sponsor":"Amgen","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imlygic (talimogene laherparepvec)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 03/07/2017","start_date":" 03/07/2017","primary_txt":" Primary completion: 08/03/2020","primary_completion_date":" 08/03/2020","study_txt":" Completion: 01/12/2023","study_completion_date":" 01/12/2023","last_update_posted":"2023-08-09"},{"id":"ede5253a-c8d1-4883-b388-b84ea206c5fb","acronym":"PROMETEO","url":"https://clinicaltrials.gov/study/NCT03802604","created_at":"2021-01-18T18:47:49.372Z","updated_at":"2024-07-02T16:35:45.290Z","phase":"Phase 1","brief_title":"Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer","source_id_and_acronym":"NCT03802604 - PROMETEO","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" HER-2 • ER • PGR • CD8 • PRF1 • FLT3LG","pipe":" | ","alterations":" HER-2 negative • PGR positive • PGR negative","tags":["HER-2 • ER • PGR • CD8 • PRF1 • FLT3LG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Imlygic (talimogene laherparepvec)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 12/10/2018","start_date":" 12/10/2018","primary_txt":" Primary completion: 04/27/2022","primary_completion_date":" 04/27/2022","study_txt":" Completion: 04/27/2025","study_completion_date":" 04/27/2025","last_update_posted":"2023-06-22"},{"id":"e20dbfa0-46b3-4de5-82c1-deb838335c51","acronym":"","url":"https://clinicaltrials.gov/study/NCT03554044","created_at":"2021-01-18T17:29:16.282Z","updated_at":"2024-07-02T16:35:48.022Z","phase":"Phase 1b","brief_title":"T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer","source_id_and_acronym":"NCT03554044","lead_sponsor":"University of California, San Francisco","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • tamoxifen • albumin-bound paclitaxel • fulvestrant • letrozole • anastrozole • exemestane • Imlygic (talimogene laherparepvec)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 02/05/2020","start_date":" 02/05/2020","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2023-05-15"},{"id":"19c3c1bd-881c-4f57-b951-9aa938fe39ec","acronym":"TEMPO","url":"https://clinicaltrials.gov/study/NCT03663712","created_at":"2021-01-18T17:58:41.983Z","updated_at":"2024-07-02T16:36:00.160Z","phase":"Phase 1","brief_title":"Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies","source_id_and_acronym":"NCT03663712 - TEMPO","lead_sponsor":"Dan Blazer III, M.D.","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imlygic (talimogene laherparepvec)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 05/09/2019","start_date":" 05/09/2019","primary_txt":" Primary completion: 10/13/2022","primary_completion_date":" 10/13/2022","study_txt":" Completion: 10/13/2022","study_completion_date":" 10/13/2022","last_update_posted":"2022-11-21"},{"id":"5c7c0e76-dd87-4e80-bf01-0ebe05aa6ba7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03458117","created_at":"2021-01-18T17:02:53.863Z","updated_at":"2024-07-02T16:36:15.107Z","phase":"Phase 1","brief_title":"T-VEC in Non-melanoma Skin Cancer","source_id_and_acronym":"NCT03458117","lead_sponsor":"University of Zurich","biomarkers":" CXCL11","pipe":"","alterations":" ","tags":["CXCL11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imlygic (talimogene laherparepvec)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 04/19/2018","start_date":" 04/19/2018","primary_txt":" Primary completion: 02/04/2022","primary_completion_date":" 02/04/2022","study_txt":" Completion: 03/15/2022","study_completion_date":" 03/15/2022","last_update_posted":"2022-03-18"},{"id":"76a9e021-0a22-4aa3-aeff-274f3b10d200","acronym":"","url":"https://clinicaltrials.gov/study/NCT02366195","created_at":"2021-01-18T11:16:05.379Z","updated_at":"2024-07-02T16:36:20.050Z","phase":"Phase 2","brief_title":"Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma","source_id_and_acronym":"NCT02366195","lead_sponsor":"Amgen","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imlygic (talimogene laherparepvec)"],"overall_status":"Completed","enrollment":" Enrollment 112","initiation":"Initiation: 04/07/2015","start_date":" 04/07/2015","primary_txt":" Primary completion: 06/26/2017","primary_completion_date":" 06/26/2017","study_txt":" Completion: 12/25/2020","study_completion_date":" 12/25/2020","last_update_posted":"2021-11-30"},{"id":"fc4905d7-3fcb-4ad3-a4cc-487be3ac09b7","acronym":"myDCTV","url":"https://clinicaltrials.gov/study/NCT03747744","created_at":"2021-01-18T18:22:47.034Z","updated_at":"2024-07-02T16:36:36.754Z","phase":"Phase 1","brief_title":"Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC)","source_id_and_acronym":"NCT03747744 - myDCTV","lead_sponsor":"Universitair Ziekenhuis Brussel","biomarkers":" PD-L1 • CD1C","pipe":"","alterations":" ","tags":["PD-L1 • CD1C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imlygic (talimogene laherparepvec)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 09/28/2018","start_date":" 09/28/2018","primary_txt":" Primary completion: 10/01/2023","primary_completion_date":" 10/01/2023","study_txt":" Completion: 10/01/2023","study_completion_date":" 10/01/2023","last_update_posted":"2020-12-29"}]